CD8A and lung carcinoma: Moreover, these agents can improve immune checkpoint inhibition by reducing the accumulation of immunosuppressive MDSCs and promoting the infiltration of cytotoxic CD8+T cells in many cancer models, including rhabdomyosarcoma, NASH-HCC, CRC, PDAC, and lung cancer [15–17, 19, 46–49].